| Identification | Back Directory | [Name]
Cintirorgon sodium | [CAS]
2055538-47-9 | [Synonyms]
Cintirorgon sodium
CINTIRORGON SODIUM;LYC 55716;LYC-55716;LYC55716
3-[(2S)-6-[3-(difluoromethoxy)-5-fluorophenyl]-4-[3-(trifluoromethyl)phenyl]sulfonyl-2,3-dihydro-1,4-benzoxazin-2-yl]-2,2-dimethylpropanoate | [Molecular Formula]
C27H24F6NNaO6S | [MOL File]
2055538-47-9.mol | [Molecular Weight]
627.53 |
| Chemical Properties | Back Directory | [InChIKey]
ACMDENFXDMXUTR-BYMHURCTNA-N | [SMILES]
S(C1C=CC=C(C(F)(F)F)C=1)(N1C[C@H](CC(C)(C)C(=O)O)OC2=CC=C(C3C=C(F)C=C(OC(F)F)C=3)C=C12)(=O)=O.[NaH] |&1:13,r| |
| Hazard Information | Back Directory | [Uses]
Cintirorgon sodium is a first-in-class, selective and orally bioavailable RORγ agonist. Cintirorgon sodium (LYC-55716) modulates gene expression of RORγ expressing T lymphocyte immune cells, resulting in enhanced effector function, as well as decreased immunosuppression, resulting in decreased tumor growth, and improved survival[1][2]. | [References]
[1] Lycera Announces Initiation of Phase 1/2a Study ARGON of Immuno-Oncology Candidate LYC-55716 in Patients with Advanced Solid Tumors. Jan 04, 2017. |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|